颅内WHO I级脑膜瘤:进展与疾病特异性生存的竞争风险分析
本研究回顾性分析单中心2003年1月至2017年12月治疗的505例颅内WHO I级脑膜瘤,采用累积发生率函数和Fine-Gray竞争风险模型分析进展与疾病特异性死亡。5年复发或脑膜瘤相关死亡风险为16.2%(95%CI[12.5,20]),5年总生存率为86.1%(95%CI[82.8,89.6])。静脉窦侵犯、切除程度和进展性脑膜瘤是疾病特异性死亡或进展的独立预后因素。
要点
- 5年复发或脑膜瘤相关死亡风险为16.2%(95%CI[12.5,20]),5年总生存率为86.1%(95%CI[82.8,89.6])。
- 静脉窦侵犯(SHR=1.8)、切除程度(SHR=0.2)和进展性脑膜瘤(SHR=7)是疾病特异性死亡或进展的独立预后因素。
- 诊断年龄<65岁(HR=1.1)和复发再手术(HR=2.6)是全因生存的预测因素。
核心结论
- 在该大系列中,WHO I级脑膜瘤治疗失败与静脉窦侵犯、不完全切除和进展性肿瘤相关;较短生存与年龄增加和复发再手术相关。
- 作者推荐在无关死亡可能较多的WHO I级脑膜瘤研究中使用累积发生率竞争风险方法,因为该方法能更准确地估计疾病风险及相关预测因素。
研究设计与样本
- 回顾性 reviewed 单中心2003年1月至2017年12月治疗的505例WHO I级脑膜瘤的病理报告和临床数据。
- 估计进展和 cause-specific mortality 的累积发生率函数,并对临床和组织学标准进行竞争风险分析。
- 中位随访时间为6.2年。
主要发现
- 505例共行530次手术切除,41例患者接受放疗(RT)。
- 数据收集时,84例患者死于脑膜瘤疾病或出现复发最终接受再手术或放疗。
- 5年复发或脑膜瘤相关死亡风险为16.2%,95%CI[12.5,20];5年总生存率为86.1%,95%CI[82.8,89.6]。
- 多变量Fine-Gray竞争风险回归中,静脉窦侵犯(SHR=1.8,95%CI[1.1,2.9],p=0.028)、切除程度(SHR=0.2,95%CI[0.1,0.3],p<0.001)和进展性脑膜瘤(SHR=7,95%CI[3.3,14.8],p<0.001)是疾病特异性死亡或脑膜瘤进展的独立预后因素。
- 诊断年龄<65岁(HR=1.1,95%CI[1,1.1],p<0.001)和复发再手术(HR=2.6,95%CI[1.4,5],p=0.00252)是全因生存的预测因素。
关键数值与推荐
- 5年复发或脑膜瘤相关死亡风险为16.2%,95%CI[12.5,20]。
- 5年总生存率为86.1%,95%CI[82.8,89.6]。
- 静脉窦侵犯SHR=1.8,95%CI[1.1,2.9],p=0.028;切除程度SHR=0.2,95%CI[0.1,0.3],p<0.001;进展性脑膜瘤SHR=7,95%CI[3.3,14.8],p<0.001。
- 诊断年龄<65岁HR=1.1,95%CI[1,1.1],p<0.001;复发再手术HR=2.6,95%CI[1.4,5],p=0.00252。
临床怎么用
- 作者推荐在无关死亡可能较多的WHO I级脑膜瘤研究中使用累积发生率竞争风险方法,因为该方法能更准确地估计疾病风险及相关预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies on meningioma are reported with inadequate allowance for competing causes of progression or death. The aim of this study was to describe the outcome of patients with intracranial WHO grade I meningioma and identify factors that may influence disease progression and cause-specific survival. METHODS: Pathology reports and clinical data of 505 WHO grade I meningiomas treated between January 2003 and December 2017 were retrospectively reviewed at a single institution. We estimated a cumulative incidence function for progression and cause-specific mortality. A competing risk analysis was conducted on clinical and histological criteria. Median follow-up was 6.2 years. RESULTS: A total of 530 surgical resections were performed on 505 cases. Forty-one patients received radiotherapy (RT). At data collection, 84 patients had died of their meningioma disease or demonstrated a recurrence eventually treated by redo surgery or RT. The risks of recurrence or meningioma-related death at 5 years were 16.2%, 95%CI[12.5, 20], whereas 5-year overall survival was 86.1%, 95%CI[82.8, 89.6]. In the multivariable Fine-Gray regression for a competing risk model, venous sinus invasion (SHR = 1.8, 95%CI[1.1, 2.9], p0.028), extent of resection (SHR = 0.2, 95%CI[0.1, 0.3], p < 0.001), and progressing meningioma (SHR = 7, 95%CI[3.3, 14.8], p < 0.001) were established as independent prognostic factors of cause-specific death or meningioma progression. In contrast, age at diagnosis < 65 years (HR = 1.1, 95%CI[1, 1.1], p < 0.001) and redo surgery for meningioma recurrence (HR = 2.6, 95%CI[1.4, 5], p = 0.00252) were predictors of the overall survival. CONCLUSIONS: In this large series, WHO grade I meningioma treatment failure correlated with venous sinus invasion, incomplete resection, and progressing tumour; shorter survival correlated with increased age and redo surgery for recurrence. We recommend the cumulative incidence competing risk approach in WHO grade I meningioma studies where unrelated mortality may be substantial, as this approach results in more accurate estimates of disease risk and associated predictors.
引用
- Champeaux C, Houston D, Dunn L, et al. Intracranial WHO grade I meningioma: a competing risk analysis of progression and disease-specific survival. Acta Neurochir (Wien). 2019. PMID: 31707459. doi:10.1007/s00701-019-04096-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。